BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
26.49
+0.28 (1.07%)
Dec 20, 2024, 4:00 PM EST - Market closed
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $2.73M in the quarter ending September 30, 2024, a decrease of -33.22%. This brings the company's revenue in the last twelve months to $217.77M, up 2,209.77% year-over-year. In the year 2023, BridgeBio Pharma had annual revenue of $9.30M, down -88.02%.
Revenue (ttm)
$217.77M
Revenue Growth
+2,209.77%
P/S Ratio
22.18
Revenue / Employee
$391,664
Employees
556
Market Cap
5.01B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
RadNet | 1.77B |
Alkermes | 1.51B |
Stevanato Group | 1.22B |
Tempus AI | 640.44M |
Corcept Therapeutics | 628.56M |
Telix Pharmaceuticals | 430.80M |
TG Therapeutics | 264.79M |
Krystal Biotech | 241.52M |
BBIO News
- 8 days ago - Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - GlobeNewsWire
- 18 days ago - Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - GlobeNewsWire
- 26 days ago - FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Benzinga
- 27 days ago - BridgeBio: Next Chapter Begins After Attruby Approval - Seeking Alpha
- 4 weeks ago - US FDA approves BridgeBio's drug for rare heart condition - Reuters
- 4 weeks ago - Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients - GlobeNewsWire
- 4 weeks ago - BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Benzinga
- 4 weeks ago - Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months - GlobeNewsWire